公开(公告)号：US09238639B2

公开(公告)日：2016-01-19

申请号：US14380215

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Nobuyuki Takakura ,  Yoshihiro Banno ,  Yoshito Terao ,  Atsuko Ochida ,  Sachie Morimoto ,  Tsuneo Yasuma ,  Minoru Ikoma ,  Kei Masuda

IPC: C07D333/60 ,  C07D417/12 ,  C07D495/04 ,  C07D333/54 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D307/84 ,  C07D333/64 ,  C07D333/70

CPC classification number: C07D333/60 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D307/84 ,  C07D333/54 ,  C07D333/64 ,  C07D333/70 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04

Abstract: The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有GOAT抑制作用的化合物，其可用于预防或治疗肥胖症等，并且具有优异的疗效。 本发明是由式（I）表示的化合物：其中各符号如说明书中所定义，或其盐。

公开(公告)号：US10968231B2

公开(公告)日：2021-04-06

申请号：US16497141

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SCOHIA PHARMA, INC

Inventor： Seiji Miwatashi ,  Yasufumi Miyamoto ,  Koji Watanabe ,  Yayoi Nakayama ,  Yuko Hitomi ,  Jumpei Aida ,  Nobuyuki Takakura ,  Hideki Furukawa ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Shizuo Kasai ,  Toshitake Kobayashi ,  Tsuyoshi Maekawa ,  Satoshi Sasaki ,  Shigemitsu Matsumoto

IPC: C07D491/052 ,  C07D211/22 ,  C07D401/12 ,  C07D401/14

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US20150018547A1

公开(公告)日：2015-01-15

申请号：US14380215

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Nobuyuki Takakura ,  Yoshihiro Banno ,  Yoshito Terao ,  Atsuko Ochida ,  Sachie Morimoto ,  Shuji Kitamura ,  Yoshihide Tomata ,  Tsuneo Yasuma ,  Minoru Ikoma ,  Kei Masuda

IPC: C07D333/60 ,  C07D307/80 ,  C07D495/04 ,  C07D417/12 ,  C07D333/70 ,  C07D333/64 ,  C07D409/12 ,  C07D405/12

CPC classification number: C07D333/60 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D307/84 ,  C07D333/54 ,  C07D333/64 ,  C07D333/70 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04

Abstract: The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有GOAT抑制作用的化合物，其可用于预防或治疗肥胖症等，并且具有优异的疗效。 本发明是由式（I）表示的化合物：其中各符号如说明书中所定义，或其盐。

公开(公告)号：US11186565B2

公开(公告)日：2021-11-30

申请号：US16499432

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji Miwatashi ,  Yasufumi Miyamoto ,  Koji Watanabe ,  Yayoi Nakayama ,  Yuko Hitomi ,  Jumpei Aida ,  Nobuyuki Takakura ,  Hideki Furukawa ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Kazuaki Takami ,  Norihito Tokunaga ,  Tomohiro Okawa ,  Akito Shibuya ,  Shizuo Kasai ,  Toshitake Kobayashi ,  Tsuyoshi Maekawa

IPC: C07D401/12 ,  C07C59/72 ,  C07D211/22 ,  C07D213/64 ,  C07D401/10 ,  C07D401/14 ,  C07D413/10

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US09776962B2

公开(公告)日：2017-10-03

申请号：US14898633

申请日：2014-08-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Jumpei Aida ,  Yayoi Yoshitomi ,  Yuko Hitomi ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Hideki Furukawa ,  Akito Shibuya ,  Koji Watanabe ,  Yasufumi Miyamoto ,  Tomohiro Okawa ,  Nobuyuki Takakura ,  Seiji Miwatashi

IPC: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

公开(公告)号：US11952344B2

公开(公告)日：2024-04-09

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya Oguro ,  Makoto Kamata ,  Shuhei Ikeda ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Shigemitsu Matsumoto ,  Hirotaka Kamitani ,  Takaharu Hirayama ,  Toshio Tanaka ,  Hiroshi Banno ,  Nobuyuki Takakura ,  Jinichi Yonemori ,  Takuya Fujimoto

IPC: C07D213/61 ,  A61K31/444 ,  A61K31/495 ,  A61P25/00 ,  A61P29/00 ,  C07D211/04 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  C07D405/02

CPC classification number: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09605000B2

公开(公告)日：2017-03-28

申请号：US14775265

申请日：2014-03-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shizuo Kasai ,  Masaki Ogino ,  Ryo Mizojiri ,  Takeshi Yamasaki ,  Hideki Hirose ,  Nobuyuki Takakura ,  Tohru Yamashita ,  Sachie Morimoto ,  Takashi Nakahata ,  Asato Kina

IPC: C07D498/10 ,  A61P3/00 ,  A61K31/424

CPC classification number: C07D498/10

Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.